J&J: terminates collaboration with Bavarian Nordic

(CercleFinance.com) - Johnson & Johnson's Janssen Pharmaceutical Companies today announced that it has terminated its collaboration and licensing agreements with Bavarian Nordic for the MVA-BN (Modified Vaccinia Ankara - Bavarian Nordic) technology for the development of potential vaccines against hepatitis B virus and human papillomavirus.


However, Janssen remains committed to its strong collaboration with Bavarian Nordic in the prevention and cure of infectious diseases - with ongoing collaborations on HIV and Ebola.

Janssen will continue to prioritise hepatitis B using alternative investigational vaccine platforms and therapies within its broad portfolio and has several ongoing studies.



Copyright (c) 2022 CercleFinance.com. All rights reserved.